On 18th August,2021, Guangzhou NVWA life Technology Co., Ltd. , a new generation assisted reproductive technology innovation company (hereinafter referred to as “Nvwa life”) has successfully completed tens of millions of RMB in angel round financing, exclusively led by JUE Capital.

In China, the low birth rate has become a major concern for China’s future economic and social development. With the implementation of supportive policies for the second and third child, many related fields have attracted attention, and the assisted reproductive market has become ont of the most attractive.

The political bureau of central committee of Chinese Communist Party held a meeting to deliberate on The Decision On Optimization Of Reproduction Policy To Advance Population For Long-term and Balanced Development, on 31st May,2021.

The meeting pointed out that reproduction policy will be further optimized so that a couple can have three children and national supportive measures should be implemented.

On 20th July,2021, according to “ State Council of Central Committee of Chinese Communist Party’s decision on Optimization Of Reproduction Policy To Advance Population Long-term and Balanced Development, the government will begin to focus on the specific problem to improve the fertility.

The prospect of the assisted reproduction industry will be more prosperous with the introduction of a serial of policies.

According to penetration rate of European and American market, Chinese assisted reproductive testing market capacity will reach 46 billion yuan per year and global market capacity will reach 100 billion yuan per year. 

The technology innovation is the important solution to infertility. Domestic doctors’ choice ratio of Artificial insemination and in vitro fertilization is about 7:19 and they usually choose in vitro fertilization when they fail to conceive for 2-3 times, according to the data released by 《Reproductive Biology and Endocrinology》

By the end of 2020, the total assisted reproduction service cycles in China are 1.303 millions with IVF cycles of 0.952 million cases.

According to the clinical date released by American Association of Reproductive Medicine, current live birth rate of IVF practice is about 25.5%. Therefore, it is urgent need for technology innovation to improve the birth rate.

By collaborating with Prof. Jie Qiao and Prof. Yang Yu from Peking University, Deputy Dean Dr. Yong Fan from The Third Affiliated Hospital of Guangzhou Medical University, Nvwa life’s founding team invented the Preimplantation DNA Methylation Screening ( PIMS) that forms the new generation IVF embryo screening technology.    

Through the collaborative clinical trial with Prof. Zijiang Chen from Shandong University, we found the birth rate of IVF embryos screened by PIMS was higher than 70%.

PIMS can simultaneously test the aneuploidy and DNA methylation level, which can screen embryos with good developmental potential to reduce the birth defect, improve the health of infants, achieve fertility optimization and reduce patient’s suffering.

PIMS can totally replace the PGS that is widely used worldwide. Nvwa life owns the key intellectual property globally form PIMS that has awarded excellent evaluation by Chinese Academy of Science.

JUE Capital indicates that Nvwa life’s new generation IVF screening technology ,PIMS, has global exclusive patent which can directly screen high-quality embryos, reducing IVF screening cost, improving healthy birth rate and fertility quality. There is very broad clinical demand for PIMS.

Meanwhile, Nvwa life also meets the national policy of Encouraging Fertility, therefor has great social value and prosperous future.

Nvwa life is dedicated to being a global innovative player for assisted reproduction.

Currently, Nvwa life has already recruited professional team with drug development, production, quality control and clinical study experience, which will dedicate to industrialize PIMS.